Collegium's 6% Q2 Growth Hides a 24% NUCYNTA Drop-Is the ADHD Turnaround Worth the Premium?

Q2 growth looks healthier than the underlying revenue mix

Collegium reported $199.9 million in Q2 revenue, up 6% year over year. But that headline figure does not tell the whole story. Following the AZSTARYS acquisition, growth looks less like broad portfolio strength and more like a partial offset between a newer ADHD asset and a shrinking legacy pain franchise.

The clearest pressure point is the NUCYNTA franchise, which fell 24% to $35.2 million, including $5.1 million from profit share on authorized generics. That kind of decline can be easy to minimize when a company also has a newer acquisition and a cleaner growth narrative.

Earnings strength does not fully offset the mix shift

The quarter also showed real operating resilience. Collegium posted Adjusted EBITDA up 8% year-over-year and Non-GAAP Adjusted EPS of $1.92, compared to $1.68 in the prior-year quarter. That helps explain why the market has been willing to focus on the company's pivot toward ADHD.

The real question is whether investors are paying for a new ADHD-led growth engine or still underwriting an older pain-cash-flow base that is slowly shrinking. If NUCYNTA continues to weaken, the market may need to reassess how much of Collegium's value still depends on legacy products. If ADHD execution holds, the current optimism becomes easier to justify.

ADHD is the main story, but the quarter is still only part of the picture

The market is understandably focused on ADHD after the NUCYNTA weakness. That reaction makes sense, but one quarter is not enough on its own. Collegium generated $46.1 million in JORNAY PM revenue, up 41% year over year, and AZSTARYS contributed $12.9 million, reflecting about a month and a half of commercial sales. That is meaningful progress, but it still sits alongside a still-declining legacy franchise.

What would strengthen the bull case

The bullish case improves if Collegium can turn commercial expansion into repeatable adoption. JORNAY PM reached an all-time high of over 30,000 prescribers, which suggests the launch footprint is broadening. If that reach starts translating into steadier repeat demand, the ADHD portfolio can begin to look more like a durable growth driver and less like a temporary substitution for legacy pain revenue.

What the market still needs to verify

The caution is straightforward: this quarter shows promise, not full validation. AZSTARYS was still in an early sales phase, and NUCYNTA remains a material part of the revenue base. Until the next few quarters show whether ADHD growth can hold up on its own, investors should treat the quarter as a positive signal rather than complete proof of a permanent rerating.